BR9913472A - Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas - Google Patents

Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas

Info

Publication number
BR9913472A
BR9913472A BR9913472-1A BR9913472A BR9913472A BR 9913472 A BR9913472 A BR 9913472A BR 9913472 A BR9913472 A BR 9913472A BR 9913472 A BR9913472 A BR 9913472A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
new
manufacturing processes
sodium alendronate
alendronate
Prior art date
Application number
BR9913472-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR9913472A publication Critical patent/BR9913472A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9913472-1A 1998-08-27 1999-08-27 Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas BR9913472A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BR9913472A true BR9913472A (pt) 2002-03-05

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913472-1A BR9913472A (pt) 1998-08-27 1999-08-27 Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas

Country Status (30)

Country Link
US (2) US6281381B1 (enExample)
EP (1) EP1107974B1 (enExample)
JP (2) JP2002523514A (enExample)
KR (2) KR20010079701A (enExample)
AT (1) ATE334993T1 (enExample)
AU (1) AU5698899A (enExample)
BG (1) BG65329B1 (enExample)
BR (1) BR9913472A (enExample)
CA (1) CA2341459A1 (enExample)
CZ (1) CZ2001629A3 (enExample)
DE (1) DE69932620T2 (enExample)
DK (1) DK1107974T3 (enExample)
EA (1) EA002739B1 (enExample)
EE (1) EE04552B1 (enExample)
ES (1) ES2270613T3 (enExample)
HR (1) HRP20010129A2 (enExample)
HU (1) HUP0203078A3 (enExample)
IL (1) IL141423A (enExample)
IS (1) IS5864A (enExample)
LT (1) LT4888B (enExample)
LV (1) LV12720B (enExample)
NO (1) NO20010957L (enExample)
NZ (1) NZ510682A (enExample)
PL (1) PL346347A1 (enExample)
PT (1) PT1107974E (enExample)
RO (1) RO122854B1 (enExample)
SI (1) SI20581B (enExample)
SK (1) SK2482001A3 (enExample)
WO (1) WO2000012517A1 (enExample)
YU (1) YU14701A (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455121T1 (de) * 2001-07-16 2010-01-15 Univ Paris 13 Herstellungsverfahren von derivate von bisphosphonaten
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
PT1753395E (pt) 2004-05-24 2010-10-21 Warner Chilcott Co Llc Forma entérica sólida de dosagem oral de um bisfosfonato contendo um agente quelante
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
DE602005016292D1 (de) * 2004-10-29 2009-10-08 Sandoz Ag Verfahren zur herstellung von glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
TWI846166B (zh) 2013-11-15 2024-06-21 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
EP0837863A4 (en) 1995-06-06 1999-06-16 Merck & Co Inc DISODIUM ALENDRONATE PREPARATIONS

Also Published As

Publication number Publication date
WO2000012517A1 (en) 2000-03-09
EE200100126A (et) 2002-06-17
SI20581A (sl) 2001-12-31
IL141423A (en) 2005-09-25
WO2000012517A9 (en) 2000-07-13
US6281381B1 (en) 2001-08-28
JP2002523514A (ja) 2002-07-30
YU14701A (sh) 2003-01-31
KR20010079701A (ko) 2001-08-22
KR20070034132A (ko) 2007-03-27
LT2001016A (en) 2001-10-25
LT4888B (lt) 2002-02-25
CZ2001629A3 (cs) 2001-08-15
EE04552B1 (et) 2005-10-17
EP1107974A1 (en) 2001-06-20
EP1107974B1 (en) 2006-08-02
HUP0203078A3 (en) 2005-01-28
RO122854B1 (ro) 2010-03-30
CA2341459A1 (en) 2000-03-09
PL346347A1 (en) 2002-02-11
DE69932620T2 (de) 2006-12-14
EP1107974A4 (en) 2001-09-26
AU5698899A (en) 2000-03-21
NO20010957D0 (no) 2001-02-26
ATE334993T1 (de) 2006-08-15
LV12720B (en) 2002-02-20
US20030065214A1 (en) 2003-04-03
EA002739B1 (ru) 2002-08-29
BG65329B1 (bg) 2008-02-29
PT1107974E (pt) 2006-10-31
US6696601B2 (en) 2004-02-24
HUP0203078A2 (hu) 2003-01-28
DE69932620D1 (de) 2006-09-14
SI20581B (sl) 2008-06-30
LV12720A (lv) 2001-09-20
IS5864A (is) 2001-02-26
EA200100184A1 (ru) 2001-10-22
HRP20010129A2 (en) 2005-04-30
NZ510682A (en) 2003-09-26
SK2482001A3 (en) 2002-01-07
ES2270613T3 (es) 2007-04-01
IL141423A0 (en) 2002-03-10
JP2009143955A (ja) 2009-07-02
BG105292A (en) 2001-12-29
DK1107974T3 (da) 2006-10-30
NO20010957L (no) 2001-04-26

Similar Documents

Publication Publication Date Title
BR9913472A (pt) Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
BR9916307A (pt) Derivados quinolina
PT782449E (pt) Processo de fabrico de unidades de dosagem por granulacao humida
BR9608996A (pt) Bloco para a construção sem argamassa de uma parede
BR9911884A (pt) Preparação farmacêutica
NO994431L (no) Ny formulering
IT8721109A0 (it) Elemento di quarzo fuso da impiegare nella fabbricazione di semiconduttori.
CO4970795A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PT833640E (pt) Composicao farmaceutica contendo lamotrigina
FI880274L (fi) Poroest skiktsilikat/ natriumsulfat-agglomerat.
TR199900548A3 (tr) Düsük kesme kuvvetli taneleme kullanilarak dozaj birimlerinin yapimi.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
BR9506235A (pt) Compostos enanciométricos únicos uso dos mesmos processos para sua preparação e de(+)-e-(-)-5-carbometoxi-6-metail-2-((3,4-dimetoxi-2-piridinil)metil )1-h-benzimidazol ou seu sal de sódio em suas for mas cristalinas para inibição de secreção de ácido gástrico e para o tratamento de doenças inflamatórias gastrointestinais e preparação farmacêutica
BR9610090A (pt) Material em bloco na forma de treliça
NO960272D0 (no) Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
FI972265A0 (fi) Menetelmä cefotaksimin valmistamiseksi ja uusia natriumsuoloja
ATE125541T1 (de) Reine kristalline form von rifapentin.
BR9803949A (pt) Cristais de maltitol de formas particulares, composições cristalinas contendo os mesmos e processo para fabriacação dos mesmos
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
NO894516D0 (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.
NO901892D0 (no) Fremgangsmaate for fremstilling av (2,1-c)(1,3)-benzodiazepiner og deres anvendelse som medikamenter.
BR0317412A (pt) Composição farmacêutica de liberação prolongada de fenitoìna de sódio e processo para sua preparação
HK1037175A (en) Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements